Vistin Pharma ASA (OSL:VISTN)
Norway · Delayed Price · Currency is NOK 18.90
+0.40 (2.16%)
At close: Sep 18, 2026
Vistin Pharma ASA Ratios and Metrics
Market cap in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 838 | 922 | 1,051 | 1,033 | 701 | 859 | |
Market Cap Growth | -19.23% | -12.24% | 1.72% | 47.47% | -18.47% | 11.06% |
Enterprise Value | 847 | 942 | 1,053 | 1,034 | 739 | 809 |
Last Close Price | 18.90 | 19.87 | 21.54 | 19.69 | 13.35 | 16.38 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 11.94 | 12.34 | 16.75 | 22.66 | - | 34.56 |
Forward PE | - | 9.45 | 9.45 | 9.45 | 9.45 | 9.45 |
PS Ratio | 1.94 | 2.04 | 2.45 | 2.36 | 2.30 | 3.08 |
PB Ratio | 2.62 | 2.81 | 3.40 | 3.20 | 2.56 | 3.12 |
P/TBV Ratio | 2.62 | 2.81 | 3.40 | 3.20 | 2.56 | 3.12 |
P/FCF Ratio | 10.57 | 15.03 | 15.67 | 14.21 | - | - |
P/OCF Ratio | 8.75 | 11.82 | 9.74 | 11.41 | - | 62.82 |
PEG Ratio | - | 1.72 | 1.72 | 1.72 | 1.72 | 1.72 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.96 | 2.08 | 2.45 | 2.36 | 2.43 | 2.90 |
EV/EBITDA Ratio | 8.16 | 8.26 | 10.20 | 12.19 | 138.71 | 18.91 |
EV/EBIT Ratio | 10.62 | 10.20 | 12.35 | 15.08 | - | 24.34 |
EV/FCF Ratio | 10.67 | 15.35 | 15.71 | 14.23 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.05 | 0.01 | 0.01 | - | 0.18 | 0.01 |
Debt / EBITDA Ratio | 0.16 | 0.01 | 0.02 | - | 7.95 | 0.03 |
Debt / FCF Ratio | 0.21 | 0.03 | 0.03 | - | - | - |
Net Debt / Equity Ratio | 0.03 | -0.04 | -0.03 | -0.08 | 0.18 | -0.12 |
Net Debt / EBITDA Ratio | 0.08 | -0.13 | -0.10 | -0.31 | 8.95 | -0.80 |
Net Debt / FCF Ratio | 0.11 | -0.24 | -0.16 | -0.36 | -0.64 | 1.88 |
Asset Turnover | 1.01 | 1.10 | 1.09 | 1.08 | 0.82 | 0.85 |
Inventory Turnover | 1.73 | 1.91 | 1.91 | 2.16 | 2.19 | 2.57 |
Quick Ratio | 1.52 | 1.34 | 1.01 | 1.24 | 0.62 | 1.92 |
Current Ratio | 2.49 | 2.35 | 2.24 | 2.43 | 1.35 | 3.36 |
Return on Equity (ROE) | 22.86% | 23.42% | 19.85% | 15.29% | -1.72% | 9.07% |
Return on Assets (ROA) | 11.64% | 14.00% | 13.53% | 10.58% | -1.03% | 6.35% |
Return on Invested Capital (ROIC) | 18.46% | 23.51% | 22.34% | 17.30% | -2.17% | 11.83% |
Return on Capital Employed (ROCE) | 22.60% | 26.20% | 26.60% | 20.50% | -2.10% | 11.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 8.38% | 8.10% | 5.97% | 4.41% | -0.67% | 2.89% |
FCF Yield | 9.46% | 6.65% | 6.38% | 7.03% | -10.68% | -2.13% |
Dividend Yield | 7.94% | 7.55% | 5.80% | 5.08% | 5.62% | 4.58% |
Payout Ratio | 63.16% | 74.15% | 123.65% | - | - | 89.17% |
Total Shareholder Return | 7.94% | 7.55% | 5.80% | 5.08% | 5.62% | 4.58% |